Long-term Management of Neovascular AMD: Meeting the Need for Improvement is organized by Vindico Medical Education.
Release Date: 2/14/2019
Expiration Date: 2/13/2020
The intended audience for this activity is retina specialists and other health care professionals involved in the treatment of patients with neovascular age-related macular degeneration (AMD).
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Age-related macular degeneration (AMD) is a leading cause of irreversible blindness and visual impairment. As prevalence of AMD continues to increase, it is estimated that nearly 3 million individuals in the United States will develop AMD by 2020. The integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapies into therapeutic protocols has significantly improved the prognosis for patients with AMD. Unfortunately, initial vision gains are not always maintained; however, continued evaluation of anti-VEGF therapies and treatment protocols are now providing visual acuity gains with long-term therapy. In this educational activity, experts in the field review intravitreal anti-VEGF treatment protocols, discuss outcomes from pinnacle clinical studies, and evaluate recent studies that demonstrate visual acuity benefits with long-term anti-VEGF therapy.
Upon successful completion of this activity, participants should be better able to:
• Evaluate new evidence-based medicine regarding the use of anti-vascular endothelial growth factor (VEGF) therapy in the long-term management of neovascular AMD.
• Assess injection protocols for their ability to optimize the long-term benefits of anti-VEGF therapy in the treatment of neovascular AMD.